simplywall.stSEP 254 min read$JNJ

Johnson & Johnson (JNJ) Phase 3 Myeloma Data Recasts Long Term Survival Expectations

Johnson & Johnson (JNJ) reported Phase 3 trial results for TECVAYLI plus DARZALEX FASPRO in relapsed/refractory multiple myeloma, showing improved survival outcomes. The data suggest potential long-term survival benefits, with modeling indicating an 86.6% projected cure fraction. Investors will watch for regulatory updates and real-world adoption.

Original reporting

simplywall.st

Published Sep 25, 2026, 9:33 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 25, 2026, 10:52 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Johnson & Johnson (JNJ) Phase 3 Myeloma Data Recasts Long Term Survival Expectations — source image — Source · simplywall.st

Decision brief

The 30-second read

$JNJBullishMed

Why it matters

The data suggests a cure fraction of 86.6% versus 0% in the control arm, implying a transformative therapy that could reshape JNJ's oncology revenue mix through 2027.

Market read

First‑report Phase 3 data could drive a near‑term price rally and longer‑term valuation uplift for JNJ and the broader oncology sector.

What to watch

Potential competition from other CAR‑T therapies and manufacturing scale constraints.

Relevance 8/10Novelty 9/10Timing: release day Sep 25 2026

Background

Johnson & Johnson announced Phase 3 MajesTEC-3 results for its CAR‑T therapy TECVAYLI combined with DARZALEX FASPRO in relapsed/refractory multiple myeloma.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBullishMedium confidence

Context

Phase 3 MajesTEC-3 data for TECVAYLI + DARZALEX FASPRO shows an 86.6% projected cure fraction, a potential catalyst for Johnson & Johnson's oncology revenue.

Expected impact

Potential upside of 5‑10% if data drives analyst upgrades and regulatory optimism.

Evidence & confidence

Data is novel and material, but impact depends on regulatory approval and payer adoption.

Market effects

Sector

Strengthens outlook for the oncology/biotech sector, may lift peers with similar pipelines.

Regional

Positive for US healthcare stocks; limited immediate effect on global markets.

Global

Highlights US pharma innovation, could influence global biotech investment sentiment.

Counterpoint

What could challenge this read

Regulatory hurdles or payer pushback could limit commercial upside despite strong data.

Key entities

company
Johnson & Johnson
US‑based healthcare conglomerate developing TECVAYLI and DARZALEX FASPRO.
product
TECVAYLI
CAR‑T therapy evaluated in MajesTEC‑3.
product
DARZALEX FASPRO
Antibody therapy combined with TECVAYLI in the trial.

Read at source ← All news

SEP 25

$JNJMed

J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?

Johnson & Johnson (JNJ) reported that its drug RYBREVANT, combined with chemotherapy, achieved a median overall survival of 34.3 months in a Phase 3 trial for advanced non-small cell lung cancer, compared to 27.9 months with chemotherapy alone. While the protocol-specified final overall-survival analysis did not reach statistical significance, a prespecified analysis accounting for crossover showed a 43% reduction in the risk of death.

insidermonkey.com3 min

SEP 25

$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min

SEP 24

$APOHighAI 9/10

Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue

Apollo Global Management (APO) is in talks to acquire Johnson & Johnson's (JNJ) orthopedics unit, DePuy Synthes, for around $20 billion, according to Bloomberg. The unit generated $9.3 billion in 2025 revenue. J&J may also consider a public spin-off. The deal could provide Apollo with a high-margin asset and J&J with liquidity for other investments.

insidermonkey.com3 min

SEP 24

$JNJMedAI 9/10

Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta

Johnson & Johnson reported positive Phase 3 trial results for Caplyta in treating manic episodes in adults with bipolar I disorder. The study met its primary endpoint, showing significant symptom reduction versus placebo by Week 3, with early improvement observed by Day 3. Results were presented at the 2026 Psych Congress Annual Meeting.

tipranks.com2 min

SEP 22

$JNJHighAI 9/10

CHMP backs expanded use of teclistamab

Johnson & Johnson announced the CHMP recommended approval for TECVAYLI (teclistamab) in adults with relapsed or refractory multiple myeloma after at least one prior therapy. The recommendation follows phase 3 results showing improved progression-free and overall survival. The company highlighted the critical need for effective immunotherapies in earlier treatment lines.

pharmatimes.com2 min